Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients

BACKGROUND: This study investigated the risk of prostate cancer in ever users and never users of rosiglitazone in diabetes patients in Taiwan. METHODS: The nationwide database of the National Health Insurance was used to enroll male patients who had a new diagnosis of type 2 diabetes mellitus at an...

Descripción completa

Detalles Bibliográficos
Autor principal: Tseng, Chin-Hsiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407244/
https://www.ncbi.nlm.nih.gov/pubmed/37560306
http://dx.doi.org/10.3389/fendo.2023.1185053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407244/
https://www.ncbi.nlm.nih.gov/pubmed/37560306
http://dx.doi.org/10.3389/fendo.2023.1185053

Ejemplares similares